Genetic testing to choose between focal or whole-gland treatment for prostate cancer
Tests tumor genetic profiling to select men with localized prostate cancer for focal therapy.
Plain-language title generated from the registry record
Registry title: Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer
Key facts
- Where
- Singapore, SingaporeSee the site
Where in Singapore
- Singapore General HospitalSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Singapore General Hospital
- Trial code
- NCT07282808
- Record updated
- 8 January 2026
- Original description
Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue. This helps reduce side effects like urinary, sexual, and bowel problems.Read full original descriptionShow less
Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer
Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue. This helps reduce side effects like urinary, sexual, and bowel problems.
In a prospective observational expansion of a phase II clinical trial (ProAMFocal), 80% of patients with small, localized prostate cancers treated with FT had no cancer recurrence at one year, and 70% at 3 years after treatment. The investigators studied the genetic makeup of each cancer, and found that certain genetic markers and cancer subtypes were better at predicting recurrence than standard clinical measures.
Based on this, the investigators are launching the FLAME-PC trial. In this study, all patients who qualify for FT will first undergo genetic profiling of their cancer. Patients with favorable profiles (low risk based on genetic markers) will receive FT, while those with high-risk profiles will be advised to undergo standard treatments like prostate removal or radiation.
The investigators current main goal is to test if genetic profiling can help us better select patients for FT. They believe that patients chosen using this method will have low recurrence rates (<10%) compared to those in their previous study (20-30%). FLAME-PC aims to show that personalized treatment based on genetic profiling can improve outcomes for prostate cancer patients, offering effective cancer control with fewer side effects.
Inclusion: Prostate Adenocarcinoma; Grade Group 2-4; MRI lesion size ≤3ml for single lesions ≤1.5ml for 2 lesions; no gross EPE; assessed to be completely ablatable with margin with focal therapy.
Exclusion: Grade Group 5 cancer; multifocal (>2) clinically significant prostate cancer; gross EPE; unablatable location (very apical, basal tumors, or otherwise determined by procedurist).